SiNtx Technologies Inc (SINT)

[CL101]

Zimmer's manufacturing facility issues resolved in China:

"We believe this development should not just help the company regain goodwill in the market but the successful run of the Chinese manufacturing facility should also help it boost the profit margins by curtailing operating expenses."

"Zimmer Biomet expects to establish a critical mass in both spine and dental departments to position it well to compete effectively and gain a plum share in these significant markets."

Additionally, the latest development should also add an impetus to the company's emerging market growth trajectory. In the recent past, Zimmer has been working hard to strengthen its foothold in the emerging markets to acquire long-term growth opportunities. (Think China Weigao deals with Amedica)

"Opportunity from emerging markets is expected to grow to $10 billion by 2018 for the Reconstructive and Trauma areas."

http://www.nasdaq.com/article/fda-passes-zimmer-biomets-zbh-zhejiang-facility-issue-cm803147


Amedica's brand new patents of 2nd. Gen worldwide patents is perfect for this (The Osteoconductivity increased 190% over current silicon nitride composition) https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017027426:

Reconstructive and Trauma areas. <<<< maxillofacial skeletal reconstruction.

https://www.ncbi.nlm.nih.gov/pubmed/12418561 and also

Bone defects repairiing & Bone Regeneration.

https://www.google.com/search?q=Reconstructive+and+Trauma&oq=Reconstructive+and+Trauma&aqs=chrome..69i57&sourceid=chrome&ie=UTF-8#q=reconstructive+and+trauma+bone+growth